Vitamin D Status and COVID-19: Some Implications

Ernest EMILION (eemilion@gmail.com)
Universite d'Orleans  https://orcid.org/0000-0001-7545-5614

Richard Emilion
Universite d'Orleans

Research

Keywords: COVID-19, Vitamin D, 25(OH)D, PTH, 1,25(OH)2D, Calcium, Cut point, Rising, Regression.

DOI: https://doi.org/10.21203/rs.3.rs-65373/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

**Background** Vitamin D is essential for the maintenance of good health and its status is defined by the level of serum 25-hydroxyvitamin (25(OH)D). Negative correlations between mean levels of 25(OH)D per country and the number of COVID-19 confirmed cases per one million population, and COVID-19 mortality per one million population, were recently observed. The aim of this study was to identify levels of 25(OH)D below which, rates of COVID-19 confirmed cases, mortality and lethality, increase significantly.

**Methods** A data table found in the literature, containing a list of twenty countries and their corresponding mean level of 25(OH)D was updated with COVID-19 latest numbers of confirmed cases and mortality rates. Cut points of 25(OH)D below which rates were significantly higher were found according to various statistical criteria: absolute difference of means, \( t \)-test \( p \)-values, between class variance, entropy. Thresholds of 25(OH)D below which there can be a significant rise of COVID-19 confirmed cases, mortality and lethality, were found performing a Gaussian kernel regression.

**Results** All the criteria yielded 25(OH)D cut off points at 50 ± 10 nmol/L for Cases and Mortality variables and at 60 ± 10 nmol/L for Lethality variable. A Gaussian kernel regression showed a significant rise in the rates of COVID-19 confirmed cases, mortality and lethality, below 25(OH)D levels of 60 ± 6 nmol/L.

**Conclusion** In this study, our method provided a reliable estimate (95 % confidence interval) of 25(OH)D levels, of 60 ± 6 nmol/L, in the range of vitamin D insufficiency, below which rates of COVID-19 confirmed cases per one million population, rates of COVID-19 mortality per one million population increased. We found that 25(OH)D levels below 50 ± 10 nmol/L, mainly in the range of vitamin D deficiency, associate with highest COVID-19 mortality rates. Therefore, we suggest that 25(OH)D concentrations should be above 60 ± 6 nmol/L to reduce morbidity and mortality during the COVID-19 pandemic.

**Background**

Vitamin D is essential for the maintenance of good health. There are two ways to get vitamin D: either orally from the diet and vitamin D supplements or dermally, through synthesis in the skin, in response to solar ultraviolet B radiation. In humans, dermal production is the major source of vitamin D. Vitamin D is hydroxylated in the liver into 25-hydroxyvitamin [25(OH)D] and subsequently in the kidney to 1,25-dihydroxy vitamin D [1,25(OH)2D]. This is the active metabolite, which stimulates intestinal calcium absorption. Vitamin D status is defined by serum 25(OH)D concentration \([1, 2]\), which is influenced in turn by various factors such as latitude and skin pigmentation \([3]\).

The production of 1,25(OH)2D is stimulated by parathyroid hormone, or parathormone (PTH). There is a negative feedback through calcium, which decreases PTH, and a direct negative feedback from 1,25(OH)2D to PTH. PTH increases the reabsorption of calcium in the kidney and stimulates bone resorption, resulting in an increase in serum calcium. When 25(OH)D availability declines, serum 1,25(OH)2D declines, and this results in reduced calcium absorption, a transient decline in serum calcium concentration, and stimulation of PTH secretion known as secondary hyperparathyroidism.
The recent outbreak and rapid spreading of severe acute respiratory syndrome COVID-19 are a global threat and primary concern worldwide, with a still uncertain outcome. Previous observational studies report independent associations between low serum concentration of 25-hydroxyvitamin D and susceptibility to acute respiratory tract infections [4]. Some authors found that vitamin D might play a protective role for COVID-19 with an association between the mean levels of vitamin D in various countries and the morbidity, and the mortality, caused by COVID-19 [5].

Our purpose was to estimate 25(OH)D levels below which rates of COVID-19 confirmed cases per one million population (/1 M), rates of COVID-19 mortality/1 M, and lethality, were higher.

**Methods**

We used the aggregated data table built by Ilie et al. in [5] with the same sample of $n = 20$ countries and their corresponding mean level of 25(OH)D, but the number of COVID-19 confirmed cases/1 M and the number of COVID-19 deaths/1 M population were updated according to the recent records of Coronavirus Disease 2019 (COVID-19) data in the WHO records [6]. Lethality variable, ratio of the number of deaths/1 M to the number of confirmed cases/1 M, was computed. It was an estimation of the probability of dying knowing that the patient is infected.

$K$-means algorithm was applied with $K = 2$ to Cases variable in order to get a partition of two clusters $\Delta$ and $\nabla$ composed of countries having a higher number of cases/1 M and a lower number of cases/1 M, respectively.

In order to find a 25(OH)D cut point below which the behavior of Cases variable statistically differs significantly from the behavior of Cases variable above that cut point, the table was first ordered in increasing order of 25(OH)D (Table 1) and spitted into a partition of two classes:

- Class 1: countries such that 25(OH)D $\leq c$
- Class 2: countries such that 25(OH)D $> c$

where $c$ denotes a 25(OH)D concentration level varying through the range of country 25(OH)D levels.

For $i = 1,2$, let $n_i$ be Class $i$ size and let $m_i$ be the mean of Cases variable in Class $i$.

The best choice of $c$ depended on various possible criteria:

- $c$ maximizes $|m_1 - m_2|$
- $c$ minimizes the $p$-value in a student $t$-test comparing $m_1$ and $m_2$, the null and the alternative hypotheses being $H_0: m_1 = m_2$ and $H_1: m_1 > m_2$, respectively
- $c$ maximizes the Between Class Variance (BCV) defined as follows:

$$BCV = \frac{n_1 (m_1 - m)^2 + n_2 (m_2 - m)^2}{n}.$$
BCV indicates how Class 1 and Class 2 differ from the whole sample and, when it is maximal, the Within Class Variance is minimal. BCV is a standard evaluation of the classification quality.

- $c$ minimizes the entropy $H$ of Class 1 - Class 2 partition defined as follows:

\[ H_i = -r \log_2(r) - (1-r) \log_2(1-r) \]
\[ r = |\text{Class } i \cap \Delta| / n_i \]
\[ H = (n_1H_1 + n_2H_2)/n. \]

Statistical procedures were implemented using R 3.6.3 software.

Confidence Intervals of 95% were adjusted bootstrap percentile intervals obtained using the 'boot.ci' function, option type = 'bca', in the 'boot' package. They were presented in the form original [le, re], where original denoted the estimation from the original sample Table 1, le and re denoting the confidence interval (CI) left and right endpoints, respectively. The number of bootstrapped samples of size $n = 20$, was $R = 1,000$. Actually, the value original was not the midpoint of the CI [le, re].

Linear regressions were applied to our sample, confidence intervals and $p$-values were derived from Dupont-Plummer formulas [7]. The rise of Cases variable was investigated by performing a Gaussian kernel regression of Cases variable on 25(OH)D concentrations using the 'npreg' function in the 'np' (nonparametric) package.

The preceding methods were applied similarly to Mortality and Lethality variables, respectively.

**Results**

The results presented below in Table 1, were obtained using the COVID-19 data recorded on 2020 July 27th [6]. No significant differences were observed in the results when using COVID-19 data recorded two weeks before or two weeks after that date because infection and mortality rates per one million population did not vary significantly.

**Table 1 Mean level of 25(OH)D in increasing order, cases of COVID-19/1 M, deaths caused by COVID-19/1 M, lethality (27th July 2020)**
The results for the number of cases, for mortality and for lethality were summarized in Table 2, Table 3 and Table 4, respectively.

*K*-means algorithm applied with $k = 2$ for example to Mortality variable, using the original Table 1 sample, yielded two clusters of countries, one cluster of 8 countries (Spain, United Kingdom, Belgium, Italy, Ireland, The Netherlands, France, Sweden) having an elevated mortality rate and a second cluster of 12 countries (Portugal, Switzerland, Denmark, Germany, Estonia, Turkey, Island, Hungary, Czechia, Norway, Finland, Slovakia) having a moderated or low mortality rate, see Table 3.

**Table 2 Statistics for the Number of Cases/1 M**
| Methods                              | Cut points $c$ (nmol/L) | Statistics for Cases/1 M                      |
|-------------------------------------|-------------------------|-----------------------------------------------|
| Sample size                         | $n = 20$                |                                               |
| Mean                                | $m = 3446 [2654 4403]$   |                                               |
| Standard Deviation                  | $s = 2112 [1634 2699]$   |                                               |
| Maximum                             | 7,858 (Sweden)          |                                               |
| Minimum                             | 404 (Slovakia)          |                                               |
| Correlation to 25(OH)D              | -0.338 ($p = 0.073$)    |                                               |
| $K$-means algorithm ($K = 2$)       |                         |                                               |
| $\Delta$: cluster of countries having a higher number of Cases/1 M |                         |                                               |
| $\tilde{\Delta}$: cluster of countries having a lower number of Cases/1 M |                         |                                               |
| Maximal Between Class Absolute Difference of means | 49.3 [40 60]           | $m_1 = 4731.17, m_2 = 2895.86$                |
| Minimal $t$-test $p$-value           | 50 [43 67]              | $p = 0.019$ at $c = 50$                       |
| Maximal Between Class Variance      | 50 [42.5 59.5]          | $BCV = 765,000$ at $c = 50$                   |
| Minimal Entropy                     | 50 [42.5 57]            | $H = 0.7137$ at $c = 50$                     |
| Gaussian Kernel Regression          |                         | Rise starting at $61 \pm 6$ nmol/L           |

Class 1: Countries such that $25$(OH)D $\leq c$

Class 2: Countries such that $25$(OH)D $> c$

**Table 3 Statistics for Mortality/1 M**
| Methods                              | Cut points c (nmol/L) | Statistics for Mortality/1 M |
|-------------------------------------|-----------------------|-----------------------------|
| Sample size                         |                       | n = 20                      |
| Mean                                |                       | m = 271 [171 396]           |
| Standard Deviation                  |                       | s = 263 [213 338]           |
| Maximum                             |                       | 847 (Belgium)               |
| Minimum                             |                       | 5 (Slovakia)                |
| Correlation with 25(OH)D            |                       | -0.276 (p = 0.119)         |
| K-means algorithm (K = 2)           |                       | Δ = {Spain, UK, Belgium, Italy, Ireland, Netherland, France, Sweden}. |
| Δ: cluster of countries having a higher mortality/1 M |                       |Deaths/1 M > 230 |
| ☐: cluster of countries having lower mortality/1 M |                       | ☐ = {Portugal, Switzerland, Denmark, Germany, Estonia, Turkey, Island, Hungary, Czechia, Norway, Finland, Slovakia}. |
| Maximal Between Class Absolute Difference of means | 50 [43 59] | $m_1 = 459.88, m_2 = 169.85$ |
| $m_1 - m_2 = 290.03$ | $m_1 > m_2 (p = 0.020)$ at $c = 50$ |
| Minimal t-test p-value              | 50 [43 56]            | p = 0.020 at $c = 50$       |
| Maximal Between Class Variance      | 50 [39 56]            | $BCV = 19,021$ at $c = 50$ |
| Minimal Entropy                     | 60 [48 72]            | $H = 0.8950$ at $c = 50$   |
| Gaussian Kernel Regression          |                       | Rise starting at 62s ± 6 nmol/L |

Class 1: Countries such that $25(OH)D \leq c$

Class 2: Countries such that $25(OH)D > c$
### Table 4: Statistics for Lethality variable

| Methods                                      | Cut points $c$ (nmol/L) | Statistics for Lethality |
|----------------------------------------------|-------------------------|---------------------------|
| Sample size $n = 20$                         | $n = 20$                |                           |
| Mean                                         | $m = 0.072 [0.050 0.097]$|                           |
| Standard Deviation                           | $s = 0.053 [0.042 0.063]$|                           |
| Maximum                                      | 0.17 (France)           |                           |
| Minimum                                      | 0.01 (Slovakia)         |                           |
| Correlation with 25(OH)D                     | - 0.195 ($p = 0.205$)   |                           |
| $K$-means algorithm ($K = 2$)                | $\Delta = \{\text{Spain, UK, Belgium, Italy, Netherland, France, Hungary}\}$ | Lethality > 0.08
| $\Delta$: cluster of countries having higher lethality |                           |                           |
| $\Delta$: cluster of countries having lower lethality |                           |                           |
| Maximal Between Class Absolute Difference of means | 60.6 [49 73]        | $m_1 = 0.084, m_2 = 0.034$|
| $m_1 - m_2 = 0.05$                           | $m_1 > m_2 (p < 0.01)$ \at $c = 60.6$ |
| Minimal $t$-test $p$-value                   | 60.6 [49 73]            | $p = 0.0055 \at c = 60.6$ |
| Maximal Between Class Variance              | 60.6 [49 73]            | $BCV = 0.0005 \at c = 60.6$ |
| Minimal Entropy                              | 60.6 [48 67]            | $H = 0.7476 \at c = 60.6$ |
| Gaussian Kernel Regression                   |                         | Rise starting at $63 \pm 6$ |

Class 1: Countries such that $25(\text{OH})D \leq c$
Class 2: Countries such that $25(\text{OH})D > c$

For the Cases variable, the cut point $c$ was found around 50 nmol/L for any of the four criteria from Table 1 sample, see Fig. 1 and Fig. 2. The boot.ci function performed the procedure on each of the $R = 1,000$ bootstrapped samples to get a 95% CI displayed in Table 2.

Linear regressions applied to our data were not significant, confidence intervals were not acute enough and $p$-values derived from Dupont-Plummer formulas [7] were bad, even using bootstrap methods. The nonparametric Gaussian Kernel regression curve of the morbidity variable on $25(\text{OH})D$, showed a rising starting at 61 nmol/L when using Table 1 data, see Fig. 3. That of mortality variable showed a rising at 62 nmol/L when using Table 1 data, see Fig. 4.

In our Table 1 sample, we noticed that there was only one country, namely Sweden, over the 6 countries having $25(\text{OH})D$ mean strictly greater than 60 nmol/L, which had an elevated mortality rate, while 7 countries over the 14 having $25(\text{OH})D$ less than 60 nmol/L, had an elevated mortality rate, see Fig. 4.

However, $25(\text{OH})D$ is certainly not the only factor that could predict mortality clusters and $\mathbb{Z}$: we observed that the AUC (Area Under Curve) of ROC curves were lower than 0.65 when performing the prediction function in the ROCR package of $R$ software.

**Discussion**

The general metabolism and actions of vitamin D are well-known, in particular as a natural immune modulator [8]. Vitamin D enhances cellular innate immunity partly through the induction of antimicrobial peptides [9, 10, 11]. It also reduces the cytokine storm induced by the innate immune system in response to viral and bacterial infections, as it was observed in COVID-19 patients [12].

In the literature, we found several thresholds of $25(\text{OH})D$ concentrations which defined vitamin D deficiency. The institute of Medicine defined vitamin D deficiency threshold at $25(\text{OH})D$ level of 30 nmol/L [13]. Vitamin D deficiency is defined at 100 nmol/L for the vitamin D Council [14], and at 50 nmol/L for the Endocrine society [15]. Our findings, which seems to be consistent with the Endocrine Society estimate, suggested that a $25(\text{OH})D$ levels below 50 ± 10 nmol/L may be linked to severe clinical outcomes of COVID-19 infection. Thus, maintaining a serum $25(\text{OH})D$ levels above 50 nmol/L could be recommended in COVID-19 disease. Indeed, Casey et al. [16] concluded that daily supplementation of vitamin D potentially offer additional protection against COVID-19 and Ebadi et al. [17] noticed that a high-dose vitamin D intervention could have a potential benefit in decreasing risk of COVID-19 severity and mortality.

Many investigators have shown that there is a threshold for serum $25(\text{OH})D$ below which secondary hyperparathyroidism may occur [18] and this threshold has been estimated in the region of 40–50 nmol/L [19, 20, 21]. As we found that COVID-19 mortality rates below vitamin D level of 50 ± 10 nmol/L are statistically higher than the rates above 50 nmol/L, it could be assumed that elevation of
PTH concentrations are involved in COVID outcomes on most of patients who have a 25(OH)D level below 50 nmol/L. Indeed, some studies have shown that elevated PTH levels are associated with increased cardiovascular risk in the general population [22, 23]. Mitnick et al. [24] have found that the liver is an important source of the circulating interleukin-6 generated in response to PTH while Casey et al. [16] have indicated that the most severe cases in COVID involving a pro-inflammatory state can lead to harmful outcomes mediated by a deregulated immune response involving interleukin-6 and other inflammatory signaling molecules. Moreover, Cheng et al. [25] have found an association between higher serum concentrations of PTH and several inflammatory markers.

It is known that 1,25(OH)2D concentrations depend mainly of 25(OH)D levels. According to White et al. [26], the influence of 1,25(OH)2D on the immune system is one of the most important factors to consider. Notably, 1,25(OH)2D regulates the immune system via the vitamin D receptor which is present on most of the immune cell types, particularly in antigen-presenting cells such as monocytes, macrophages and dendritic cells. According to Mangin et al. [27], circulating levels of 25(OH)D may not be an accurate reflection of vitamin D status because among patients with systemic inflammatory diseases, 1,25(OH)2D might be elevated so that low serum 25(OH)D, despite adequate photosynthesis of vitamin D, could be a consequence of an inflammatory process. The authors indicated that measuring both 25(OH)D and 1,25(OH)2D provide a true picture of vitamin D status rather than measuring 25(OH)D alone. Therefore, measuring 1,25(OH)2D as a marker of inflammation in each stage of clinical evolution of COVID-19 patients could be in one's interest.

Concerning the role of calcium concentration in COVID-19 mortality, Lippi et al. [28] found that COVID-19 pandemic severity is in part associated with lower serum concentrations of calcium. It is well-known that the ionic concentration of calcium, which is highly correlated to 25(OH)D and to 1,25(OH)2D, appears as the major factor influencing the secretion rate of PTH [29]. PTH plays a critical role in calcium homeostasis, defending against hypocalcemia by acting on target organs such bone and kidney in order to stimulate bone resorption, to promote renal conservation of calcium, and to induce production of 1,25(OH)2D, which in turn enhances intestinal calcium absorption [30]. Moreover, Goodman et al. [31] noticed that a slight decrease in ionized calcium triggers the release of PTH from the parathyroid glands, suggesting that patients with severe COVID-19 and low calcium concentrations may have high levels of PTH that could worsening COVID-19 issues. More studies are needed to investigate this suggestion.

In the past, vitamin D deficiency was identified by the presence of bone diseases, essentially either rickets or osteomalacia. More recently, the term vitamin D insufficiency has been used to describe suboptimal levels of serum 25(OH)D that might be associated with other disease outcomes [32]. According to Holick [33], Vitamin D insufficiency is now recognized as 25(OH)D concentrations of 52–72 nmol/L. In our study we found a 25(OH)D threshold of 60 ± 6 nmol/L below which there is a significant rise in the number of COVID-19 cases and mortality and lethality. Such a threshold is in the range of vitamin D insufficiency. It could be suggested that patients with vitamin D insufficiency might have harmful outcomes with COVID-19 before reaching status of vitamin D deficiency. Mc Kenna et al. found that when serum 25(OH)D concentrations are in the range of vitamin D insufficiency, PTH levels can be slightly elevated but are still
in the normal range [34]. This was confirmed in the results presented in Emilion et al. study [20]: the regression curve of PTH concentrations on 25(OH)D concentrations showed a small rise of PTH levels at 59 nmol/L, a plateau in the range 49–59 nmol/L and a main rise at 49 nmol/L. Moreover, when patient becomes vitamin D insufficient and deficient, the increase in PTH levels result in normal or elevated levels of 1,25(OH)2D [34]. Then, 1,25(OH)2D assay could be useless as a measure of vitamin D status [33].

In this study, we were not informed of PTH levels, 1,25(OH)2D levels, and calcium concentrations of the patients with COVID-19 from countries. Though the vitamin D cut-points of 50 ± 10 nmol/L should not be interpreted as an optimal vitamin D status, it could be used in the monitoring of vitamin D supplementations in COVID-19 syndrome. Future works need at least to take in account, for patients with COVID-19 from different stages of clinical evolution, measurements of concentrations of 25(OH)D, 1,25(OH)2D, calcium and PTH in order to elaborate reliable protocols of vitamin D-calcium supplementations and to realize a more efficient clinical monitoring of COVID-19 infection.

**Conclusion**

We identified 25(OH)D levels, of 60 ± 6 nmol/L, in the range of vitamin D insufficiency, below which rates of COVID-19 confirmed cases per one million population, and rates of COVID-19 mortality per one million population increased. We found that below 25(OH)D levels, of 50 ± 10 nmol/L, mainly in the range of vitamin D deficiency, rates of COVID-19 mortality were the highest. Therefore, we suggest that 25(OH)D concentrations should be above 60 ± 6 nmol/L to reduce morbidity and mortality during the COVID-19 pandemic. Future works could investigate other potential roles of vitamin D status in the evolution of the COVID-19 syndrome.

**Abbreviations**

COVID-19 = Corona Virus Disease 2019. /1 M = per 1 million population, nmol/L = nano moles per liter, BCV = Between Class Variance, CI = Confidence Interval

**Declarations**

*Ethics approval and consent to participate*

Not applicable

*Consent for publication*

Not applicable

*Availability of data and materials*

The dataset used and analyzed during the current study is available from the corresponding author on reasonable request.
**Competing Interest**
Not applicable

**Funding**
Not applicable

**Authors’ contributions**
EE initiated the medical problem and wrote the Abstract, the Background, the Discussion and the Conclusion sections. RE analyzed the data, proposed the statistical methods, implemented the statistical procedures, and wrote the Methods and Results parts. All authors read and approved the final manuscript.

**Acknowledgments**
Not applicable

**Authors’ information**
EE obtained is PhD in medicine from University of Paris VI. He is a medicine Doctor at Community Clinic, Paris, France. RE obtained is PhD in pure mathematics from University Paris VI. He is an emeritus professor of applied mathematics at Denis Poisson Institute, University of Orléans, France.

**Footnotes**
Not applicable

**References**
1. Bandeira F, Griz L, Dreyer P, Eufrazino C, Bandeira C. and Freese E. Vitamin D Deficiency: A Global Perspective. Arq. Bras. Endocrinol. Metab. 2006;50:4, 640 – 646.
2. Webb AR., Pilbeam C, Hanafin N. and Holick MF. An evaluation of the relative contributions of exposure to sunlight and diet to the circulating concentrations of 25-hydroxyvitamin D in an elderly nursing home population in Boston. Am. J. Clin. Nutr. 1990;51: 1075 – 81.
3. Holick MF. The use and interpretation of assays for vitamin D and its metabolites. J. Nutr. 1990;120 :1464 – 9.
4. Cannell JJ, Vieth R, Umhau JC et al. Epidemic influenza and vitamin D. Epidemiol Infect. 2006;356:1129–1140;doi:10.1017/S0950268806007175.
5. Ilie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clinical and Experimental Research. 2020; https://doi.org/10.1007/s40520-020-01570-8
6. Zheng LY, Guo XS, He B, Sun LJ, Peng Y, Dong SS, et al. Genome data from sweet and grain sorghum (Sorghum bicolor). GigaScience Database. 2011. http://dx.doi.org/10.5524/100012.

7. Dupont WD, Plummer WD Jr. Power and Sample Size Calculations for Studies Involving Linear Regression. Controlled Clinical Trials. 1998;19:589-601.

8. Hossein-nezhad A, Holick MF. Vitamin D for Health: A Global Perspective. Mayo Clin Proc. 2013 July;88(7): 720–755. doi:10.1016/j.mayocp.2013.05.011.

9. Liu, PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT Schaubert J, Wu K, Meinken, C et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006;311:1770-1773.

10. Adams JS, Ren S, Liu PT, Chun RF, Lagishetty V, Gombart AF, Borregaard N, Modlin RL, Hewison, M. Vitamin d-directed rheostatic regulation of monocyte antibacterial responses. J. Immunol. 2009;182:4289–4295.

11. Laaksi I. Vitamin D and respiratory infection in adults. Proc. Nutr. Soc. 2012;71:90–97.

12. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020,395:497-506.

13. Ross AC, Manson JE, Abrams SA, Aloia JF et al. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know. The Journal of Clinical Endocrinology & Metabolism. 2011;doi.org/10.1210/jc.2010-2704.

14. Holick MF. Vitamin D deficiency. N Engl J Med.2007;357:266-281.

15. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA,Heaney RP, Murad MH, Weaver CM & Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. 2011;96:1911–1930.

16. Casey AH , Cobbold PH, Church FC. Potential Role of Vitamin D in the Elderly to Resist COVID-19 and to Slow Progression of Parkinson's Disease. Brain Sci. 2020;10(5):284. doi: 10.3390/brainsci10050284.

17. Ebadi M, Montano-Loza AJ. Perspective: improving vitamin D status in the management of COVID-19. European Journal of Clinical Nutrition. 2020; doi:10.1038/s41430-020-0661-0.

18. Chapuy MC, Prezioso P, Mauner M, Arnaud S, Galan P, Hercberg S, Meunier PJ. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporosis Int. 1997;7:439-43.

19. Aloia JF, Talwar SA, Pollack S, Feuerman M and Yeh JK (2006) Optimal vitamin D status and serum parathyroid hormone concentrations in African American women. Am. J. Clin. Nutr. 2006; 84:602 – 9.

20. Emilion E, Emilion R. Estimation of the 25(OH) Vitamin D Threshold Below Which Secondary Hyperparathyroidism May Occur Among African Migrant Women in Paris. J Vitam Nutr Res. 2011 Jul;81(4):218-24. doi: 10.1024/0300-9831/a000073.
21. Keser I, Cvijetić S, Bituh M, Rumora Samarin I, Ilich JZ, Colić Barić I, Rumbak I. Vitamin D and Parathyroid Hormone in Relation to Bone Health in Croatian Women. Arch Osteoporos. 2018 Jun 24;13(1):69. doi: 10.1007/s11657-018-0483-z.

22. Pilz S, Tomaszczik A, Drechsler C, Ritz E, Boehm BO, Grammer TB and März W. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Oxford Journals Medicine European Heart Journal. 2010; 31/13:1591 – 1598.

23. Bhuriya MD, Li S, Chen SC, McCullough PA. and Bakris GL. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD Stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP). American J Kidney Dis. 2009;53(4 Suppl 4):S3-10. doi: 10.1053/j.ajkd.2008.11.029.

24. Mitnick MA, Grey A, MasiukiewiczU, Bartkiewicz M, Rios-VelezL, Friedman S, Lieming X, Horowitz MC, Insogna K. Parathyroid hormone induces hepatic production of bioactive interleukin-6 and its soluble receptor. Am. J. Physiol. Endocrinol. Metab. 2001;280:405-12.

25. Cheng SP, Liu CL, Liu TP, Hsu YC, Lee JJ. Association between Parathyroid Hormone Levels and Inflammatory Markers among US Adults. Mediators Inflamm. 2014; doi: 10.1155/2014/709024.

26. White JH. Vitamin D signaling, infectious diseases, and regulation of innate immunity. Infect Immun. 2008;76(9):3837–43.

27. Mangin M, Sinha R, Fincher K. Inflammation and vitamin D: the infection connection. Inflamm. Res. 2014 ;63:803–819 doi 10.1007/s00011-014-0755-z.

28. Lippi G, South AM and Henry BM. Electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19). Annals of Clinical Biochemistry.2020: 57(3) 262–265.

29. Buckle RM. The regulation of calcium metabolism. Proc. roy. Soc. Med. 1970;63:871-5.

30. Fleet JC, Schoch RD. Molecular Mechanisms for Regulation of Intestinal Calcium Absorption by Vitamin D and Other Factors. Crit Rev Clin Lab Sci. 2010;47(4):181-95.

31. Goodman WG, Belin TR, Salusky IB. In vivo assessments of calcium-regulated parathyroid hormone release in secondary hyperparathyroidism. Kidney Int. 1996;50:1834-44.

32. Thacher TD, Clarke BL. Vitamin D Insufficiency. Mayo Clin Proc. 2011;86(1):50-60.

33. Michael F. Holick, Ph.D., M.D. Vitamin D status: Measurement, interpretation and clinical application. Ann Epidemiol. 2009; 19(2): 73–78. doi:10.1016/j.annepidem.2007.12.001.

34. McKenna MJ, Freaney R. Secondary Hyperparathyroidism in the Elderly: Means to Defining Hypovitaminosis D. Osteoporos Int. 1998;8 Suppl 2:S3-6. doi: 10.1007/pl00022725.

**Figures**
Figure 1

Morbidity variable: Cut point for Difference of means and p-values criteria. Cut point c varying through the range of 25(OH)D in Table 1 sample. Class 1: Countries such that 25(OH)D ≤ c. Mean of Cases in Class 1 = m1. Class 2: Countries such that 25(OH)D > c. Mean of Cases in Class 2 = m2. |m1 – m2| was maximal at c = 49.3 nmol/L (left panel) t-test p-value was minimal at c = 50 nmol/L (right panel)
Figure 2

Morbidity variable: Cut point for BCV and Entropy criteria. Cut point c varying through the range of 25(OH)D in Table 1. Sample Class 1: Countries such that 25(OH)D ≤ c. Mean of Cases in Class 1 = m1.

Class 2: Countries such that 25(OH)D > c. Mean of Cases in Class 2 = m2. Between Class Variance (BCV) was maximal at c = 50 nmol/L (left panel). Partition Entropy H was minimal at c = 50 nmol/L (right panel).
Figure 3

Gaussian Kernel regression of morbidity variable on 25(OH)D. Rising started at 61 nmol/L. K-means algorithm applied to mortality variable yielded a cluster of countries having a high morbidity rate (point up triangle) and a cluster of countries having a low morbidity rate (point down triangle). The regression curve separated the two clusters.
Figure 4

Gaussian Kernel regression of mortality variable on 25(OH)D. Rising started at 62 nmol/L. K-means algorithm applied to mortality variable yielded a cluster of countries having a high morbidity rate (point up triangle) and a cluster of countries having a low morbidity rate (point down triangle). The regression curve separated the two clusters.